Analysis of epidemiology, clinical features and management of erysipelas

International Journal of Dermatology

Volumn 49, Issue 9, 2010, Pages 1012-1017

  Krasagakis, Konstantin ^a   Valachis, Antonios ^a   Maniatakis, Panagiotis ^a   Krüger Krasagakis, Sabine ^a   Samonis, George ^a   Tosca, Androniki D ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; C REACTIVE PROTEIN; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; LINCOZAMIDE DERIVATIVE; MACROLIDE; PENICILLIN G; QUINOLONE; UNCLASSIFIED DRUG; VANCOMYCIN;

ABDOMEN; ADULT; AEROMONAS HYDROPHILA; AGED; ARM; ARTICLE; BACTERIUM CULTURE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; ENTEROCOCCUS FAECALIS; ERYSIPELAS; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; FACE; FEMALE; FEVER; GREECE; HUMAN; INSECT BITE; LABORATORY DIAGNOSIS; LEG; LEUKOCYTE COUNT; LYMPHEDEMA; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PAIN; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; SKIN ALLERGY; SKIN DISEASE; SKIN INJURY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS HOMINIS; SWELLING; TREATMENT RESPONSE; VEIN INSUFFICIENCY;

BLOOD SEDIMENTATION; CELLULITIS; ERYSIPELAS; ERYTHEMA; FEMALE; FEVER; GREECE; HUMANS; MALE; MIDDLE AGED; PAIN; PENICILLIN G; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77956133284     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2010.04464.x     Document Type: Article

References (32)

1. Grosshans EM. The red face: erysipelas. Clin Dermatol 1993, 11:307-313.
2. Bratton RL, Nesse RE. St. Anthony's fire: diagnosis and management of erysipelas. Am Fam Phys 1995, 51:401-404.
3. Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med 1996, 334:240-245.
4. Chartier C, Grosshans E. Erysipelas: an update. Int J Dermatol 1996, 35:779-781.
5. Bonnetblanc JM, Bedane C. Erysipelas: recognition and management. Am J Clin Dermatol 2003, 4:157-163.
6. Denis F, Martin C, Ploy M. Erysipelas: microbiological and pathogenic data. Ann Dermatol Venereol 2001, 128:317-325.
7. Jorup-Rönström C. Epidemiological, bacteriological and complicated features of erysipelas. Scand J Infect Dis 1986, 18:519-524.
8. Hugo-Persson M, Norlin K. Erysipelas and group G Streptococci. Infection 1987, 15:184-187.
9. Morris A. Cellulitis and erysipelas. Clin Evid 2006, 15:2207-2211.
10. Stevens DL, Bisno AL, Chambers HF. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005, 41:1373-1406.
11. Raghavan M, Linden PK. Newer treatment options for skin and soft tissue infections. Drugs 2004, 64:1621-1642.
12. York MK, Gibbs L, Perdreau-Remington F, Brooks GF. Characterization of antimicrobial resistance in Streptococcus pyogenes isolates from the San Francisco Bay area of northern California. J Clin Microbiol 1999, 37:1727-1731.
13. Goettsch WG, Bouwes Bavinck JN, Herings RMC. Burden of illness of bacterial cellulitis and erysipelas of the leg in the Netherlands. J Eur Acad Dermatol Venereol 2006, 20:834-839.
14. Jorup-Rönström C, Britton S. Recurrent erysipelas: predisposing factors and costs of prophylaxis. Infection 1987, 15:105-106.
15. Eriksson B, Jorup-Ronstrom C, Karkkonen K. Erysipelas: clinical and bacteriologic spectrum and serological aspects. Clin Infect Dis 1996, 23:1091-1098.
16. Ronnen M, Suster S, Schewach-Millet M, Modan M. Erysipelas: changing faces. Int J Dermatol 1985, 24:169-172.
17. Dupuy A, Benchikhi H, Roujeau JC. Risk factor for erysipelas of the leg (cellulitis): case-control study. BMJ 1999, 318:1591-1594.
18. Mokni M, Dupuy A, Denguezli M. Risk factors for erysipelas of the leg in Tunisia: a multicenter case-control study. Dermatology 2006, 212:108-112.
19. Lazzarini L, Conti E, Tositti G, de Lalla F. Erysipelas and cellulitis: clinical and microbiological spectrum in an Italian tertiary care hospital. J Infection 2005, 51:383-389.
20. Dupuy A. Descriptive epidemiology and knowledge of erysipelas risk factors. Ann Venereol 2001, 128:312-316.
21. Bartholomeeusen S, Vandenbroucke J, Truyers C. Epidemiology and comorbidity of erysipelas in Primary Care. Dermatology 2007, 215:118-122.
22. Chartier C, Grosshans E. Erysipelas. Int J Dermatol 1990, 29:459-467.
23. Pavlotsky F, Amrani S, Trau H. Recurrent erysipelas: risk factors. J Dtsch Dermatol Ges 2004, 2:89-95.
24. Boycott JA. Seasonal variations in streptococcal infections. Lancet 1966, 26:706-707.
25. Leppard BJ, Seal DV, Colman G, Hallas G. The value of bacteriology and serology in the diagnosis of cellulitis and erysipelas. Br J Dermatol 1985, 112:559-567.
26. Bishara I, Golan-Cohen A, Robenshtok E. Antibiotic use in patients with erysipelas: a retrospective study. Isr Med Ass J 2001, 3:722-724.
27. Perl B, Gottehrer NP, Raveh D. Cost-effectiveness of blood cultures for adult patients with cellulitis. Clin Infect Dis 1999, 29:1483-1488.
28. Bernard P, Plantin P, Roger H. Roxithromycin versus penicillin in the treatment of erysipelas in adults: a comparative study. Br J Dermatol 1992, 127:155-159.
29. Leman P, Mukherjee D. Flucloxacillin alone or combined with benzylpenicillin to treat lower limb cellulitis: a randomized controlled trial. Emerg Med J 2005, 22:342-346.
30. Daniel R. Azithromycin, erythromycin and cloxacillin in the treatment of infections of skin and associated soft tissues. European Azithromycin Study Group. J Int Med Res 1991, 19:433-445.
31. Musette P, Benichou J, Noblesse I. Determinants of erysipelas for superficial cellulitis (erysipelas) of the leg: a retrospective study. Eur J Int Med 2004, 15:446-450.
32. Jorup-Rönström C, Britton S, Gavlevik A. The course, costs and complication of oral versus intravenous therapy of erysipelas. Infection 1984, 12:390-394.